NGM stock left Nasdaq as the biotech went private

Published on 10/01/2026 at 04:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NGM stock left Nasdaq on April 5, 2024, when NGM Biopharmaceuticals became privately held. Its pipeline update followed on February 24, 2025.

NGM, US62921N1006, Illustration mit AI erstellt.

NGM Biopharmaceuticals (ISIN US62921N1006) stock left Nasdaq on April 5, 2024, when the biotechnology company became a privately held subsidiary. The transaction valued NGM at USD 135.0 million and changed the investment story from public-market trading to clinical development funded by private capital.

Take-private changed the security

According to EdgeChat, affiliates of The Column Group completed the tender offer on April 5, 2024. The deal paid USD 1.55 per share in cash, represented a fully diluted equity value of USD 135.0 million and carried an 80.00 percent premium to the December 29, 2023 closing price.

All NGM shares ceased trading on Nasdaq before the market opened on April 5, 2024. That date is the key reference point for investors searching for NGM stock because the former public listing does not provide a current exchange quotation.

Private funding supports two programs

Three months after the transaction, NGM announced a USD 122.0 million Series A financing led by The Column Group. EdgeChat reports that the financing was intended to support a registrational trial for aldafermin in primary sclerosing cholangitis and a Phase 2 study of NGM120 in hyperemesis gravidarum.

The funding also marked a sharp pipeline reset. NGM had reached 10 clinical-stage programs at its peak, while the private company later advanced two core programs, according to EdgeChat. For investors, the comparison shows why the former ticker now describes a corporate history rather than an actively traded stock.

EMERALD reached Phase 2

NGM's investor-relations page reported on February 24, 2025, that the first participant had been dosed in the EMERALD Phase 2 clinical study of NGM120 for hyperemesis gravidarum. The update gives the private company a concrete clinical milestone after the 2024 financing and identifies NGM120 as the lead near-term development event.

As of September 2026, NGM operated as a privately held biotechnology company focused on its two remaining programs, according to EdgeChat. The former Nasdaq listing, the USD 135.0 million buyout value and the USD 122.0 million Series A therefore frame NGM's transition from public equity to private drug development.

NGM stock has private status

NGM stock has no active Nasdaq session to report on October 1, 2026. The relevant milestones are the April 5, 2024 delisting, the July 2024 financing and the February 24, 2025 EMERALD dosing update.